News for PTC Therapeutics, Inc. (PTCT)

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (”œPTC” or the ”œCompan

PR NewswireNEW YORK, June 7, 2025 NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics,

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (”œPTC” or the ”œCompan

RBC Capital's analyst, Brian Abrahams, has increased the price target for PTC Therapeutics (PTCT) from $58 to $60, while maintaining an Outperform rating for th

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (”œPTC” or the ”œCompan

RBC Capital maintains its Outperform rating for PTC Therapeutics (PTCT), citing positive indirect outcomes from the FDA's agreement with uniQure (QURE) regardin

PR NewswireNEW YORK, June 1, 2025 NEW YORK, June 1, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics,

On May 27, 2025, Wells Fargo analyst Tiago Fauth announced a revised price target for PTC Therapeutics (PTCT). The firm has increased its price target from $68.

Wells Fargo has increased its price target for PTC Therapeutics (PTCT) from $68 to $74, while maintaining an Overweight rating. The revision stems from a favora

PR NewswireNEW YORK, May 26, 2025 NEW YORK, May 26, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics,

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2025 Earnings Call May 6, 2025 4:30 PM ETCompany ParticipantsEllen Cavaleri - Head, Investor RelationsMatthew Klein...

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 0.2% on Monday. The Dow traded up 0.21% to 41,406.25 while the NASDAQ ...

PR NewswireWARREN, N.J., May 1, 2025 WARREN, N.J., May 1, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that on April 25, 2025

PTC Therapeutics (PTCT) has approved equity compensation packages for 12 new employees under Nasdaq Listing Rule 5635(c)(4). The grants include 7,000 st

PTC Therapeutics (PTCT) gains European endorsement for its phenylketonuria treatment, Sephience. Analysts predict a potential 26.81% upside for PTCT wit

PR NewswireWARREN, N.J., April 25, 2025 - Label includes full spectrum of PKU patients -- European launch preparations underway -WARREN, N.J., April 25, 20

PTC Therapeutics (PTCT) has reported a significant step forward for its drug Sephience, known scientifically as sepiapterin, aimed at treating individuals with